The Extended Safety and Efficacy of Indobufen in Conjunction With P2Y12 Receptor Inhibitors Among Patients Undergoing Revascularization: A Meta‐Analysis and Overview
Cardiovascular Therapeutics · 2025
DOI: 10.1155/cdr/5374818 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Ming Yi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Liuyang Hospital of Traditional Chinese Medicine, Liuyang, China. Hauptthemen laut MEDLINE: Coronary Artery Disease, Dual Anti-Platelet Therapy, Myocardial Revascularization, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, Shenzhen Fundamental Research Program.
Abstract (Originalsprache)
Background/Objectives Dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor for platelets, is crucial for the prevention of cardiac and systemic ischemic events in patients with coronary artery disease who have undergone revascularization procedures. Although indobufen is suggested as an alternative for individuals who exhibit intolerance to aspirin, the long‐term safety and efficacy of indobufen‐based DAPT treatment for the prevention of cardiac and systemic ischemic events in these patients remain ambiguous. This meta‐analysis seeks to examine the long‐term safety and efficacy of DAPT based on indobufen in the context of revascularization procedures for patients.
Methods
A thorough search was performed across PubMed, Embase, the Cochrane Library, Web of Science, ClinicalTrials.gov, and CNKI, covering all records from each database’s inception to October 10, 2024. Included were randomized trials analyzing oral DAPT antiplatelet agents for coronary artery disease patients who received revascularization. Two reviewers independently handled the selection process: screening articles, overview, extracting data, and assessing study quality in accordance with PRISMA guidelines. The pooled data were later subjected to analysis using a random‐effects model meta‐analysis.
Results
The final analysis included three randomized controlled trials, which yielded the following findings regarding major adverse cardiovascular and cerebrovascular events (MACCEs): The relative risk (RR) was 1.58 (95% CI, 0.72–3.38); for BARC Type 2, 3, or 5 bleeding events, the RR was 0.35 (95% CI, 0.18–0.67); and for gastrointestinal intolerance events, the RR was 0.06 (95% CI, 0.03–0.18).
Conclusions
Indobufen‐based DAPT may potentially increase the risk of ischemic events without compromising safety for revascularization, as its upper RR limit exceeds 1 for MACCEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Liuyang Hospital of Traditional Chinese Medicine, Liuyang, China.
- Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, (Shenzhen Sun Yat-sen Cardiovascular Hospital), Shenzhen, China.
- Department of Cardiology, The Fourth Hospital of Changsha, Changsha Hospital Affiliated to Hunan Normal University, Changsha, China.
ORCID-Profile: Ming Yi, Qing Cao, Yang-Hui Sheng, Lu Wu, Xiao Ke
Förderung
- Natural Science Foundation of Hunan Province
- Shenzhen Fundamental Research Program
Zitieren
APA
Yi, M., Cao, Q., Sheng, Y. H., Wu, L., & Ke, X. (2025). The Extended Safety and Efficacy of Indobufen in Conjunction With P2Y12 Receptor Inhibitors Among Patients Undergoing Revascularization: A Meta‐Analysis and Overview. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/5374818
Vancouver
Yi M, Cao Q, Sheng YH, Wu L, Ke X. The Extended Safety and Efficacy of Indobufen in Conjunction With P2Y12 Receptor Inhibitors Among Patients Undergoing Revascularization: A Meta‐Analysis and Overview. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/5374818
BibTeX
@article{Yi2025,
author = {Yi, Ming and Cao, Qing and Sheng, Yang-Hui and Wu, Lu and Ke, Xiao},
title = {The Extended Safety and Efficacy of Indobufen in Conjunction With P2Y12 Receptor Inhibitors Among Patients Undergoing Revascularization: A Meta‐Analysis and Overview},
journal = {Cardiovascular Therapeutics},
year = {2025},
doi = {10.1155/cdr/5374818}
}
EUVIMED